Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Akebia Therapeutics Inc

AKBA ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$0.56

▼ -3.95%

Market Cap $155.79M · Vol 515.63K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$155.79M

Micro Cap

Div Yield

N/A

EPS Growth

-600.00%

YoY

RSI (14)

13.43

Momentum

Beta

0.18

vs Market

52W High

$3.19

81.62% below

52W Low

$0.54

2.49% above

Volume

515.63K

Avg 557.67K

P/B

13.10

Price-to-book

ROE

N/A

Return on equity

Free Float

98.06%

Public shares

Shariah Compliance8 STANDARDS

✗ Akebia Therapeutics Inc (AKBA) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AKBA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-19.17%

-42.63%

-55.38%

-60.41%

YTD

-65.08%

-81.20%

-33.05%

-80.68%

Financials & Valuation

TTM · Annual

Total Revenue	$236.20M
Net Income	$-5,345,000.00
Revenue Growth (YoY)	-21.36%
Gross Margin	82.91%
Operating Margin	11.01%
Net Profit Margin	-2.26%
ROE	N/A
ROA · ROIC	-1.25% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	1.75
P/B	13.10
P/FCF	6.91
EPS Growth	-600.00%
Outstanding Shares	277.11M

Technical Indicators

50-Day SMA	$0.87
200-Day SMA	$1.17
RSI (14)	13.43
Beta	0.18
52-Week High	$3.19
52-Week Low	$0.54

Volume Today	515.63K
Avg Daily Volume (30D)	557.67K
Relative Volume	0.92x
Volatility (10D)	53.29
Volatility (30D)	58.32
Free Float	98.06%

Analyst Consensus

BUY

Current Price $0.56

Mean Target $3.92

52W Low$0.54 52W High$3.19

Current

Target

$0.54 $3.19

Current Analyst target

+596.67% upside potential · 6 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001T922S9

ISINUS00972D1054

CountryUSA

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeUNT Unit

Similar Halal Stocks

LLY Eli Lilly and Company +2.83% JNJ Johnson & Johnson +3.81% ABBV AbbVie Inc. +0.14% NVS Novartis AG +1.52% NOVN.S Novartis AG +1.58%

Company Profile

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). The Company's development pipeline includes mid-stage rare kidney disease pipeline assets (praliciguat and AKB-097) and early-stage pipeline assets (AKB-9090 and AKB-10108), which are HIF molecules.